RedHill Biopharma (RDHL) Gains from Investment Securities (2014 - 2015)
RedHill Biopharma (RDHL) posted quarterly Gains from Investment Securities of -$889006.0 for Q4 2015, down 347.63% year-over-year from $359000.0 in Q4 2014, and down 87086.89% quarter-over-quarter from $1022.0 in Q3 2015.
RedHill Biopharma (RDHL) Gains from Investment Securities (2014 - 2015) Analysis & Trends
RedHill Biopharma (RDHL) has reported Gains from Investment Securities for 2 consecutive years, with -$889006.0 the latest figure, recorded in Q4 2015.
- In Q4 2015, Gains from Investment Securities fell 347.63% year-over-year to -$889006.0; the TTM figure through Dec 2015 stood at -$1.6 million (changed N/A YoY), while the FY2015 annual figure was -$888000.0, down 344.0% from the prior year.
- Gains from Investment Securities declined to -$889006.0 in Q4 2015 per RDHL's latest filing, from $1022.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $359000.0 in Q4 2014 and bottomed at -$1.1 million in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -889,006.00 |
| Dec 31, 2015 | -889,006.00 |
| Sep 30, 2015 | 1,022.00 |
| Sep 30, 2015 | 1,022.00 |
| Dec 31, 2014 | 359,000.00 |
| Dec 31, 2014 | 359,000.00 |
| Sep 30, 2014 | -1.09 Mn |
| Sep 30, 2014 | -1.09 Mn |